PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
18701868-1	2008	Pegylated liposomal doxorubicin (Doxil: PLD) is a liposome-encapsulated form of doxorubicin modified with polyethylene glycol that has been approved for the treatment of AIDS-related Kaposi"s sarcoma.	liposomal doxorubicin	33-38	glycosylphosphatidylinositol specific phospholipase D1	Homo sapiens	40-43	
14656277-4	2003	Trials presently testing this, make use of either epirubicin (EPI) or pegylated liposomal doxorubicin (PLD: Doxil(R)/Caelyx(R)).	liposomal doxorubicin	108-113	glycosylphosphatidylinositol specific phospholipase D1	Homo sapiens	103-106	
15717739-3	2004	Pegylated liposomal doxorubicin (Doxil/Caelyx [PLD]), is the only liposomal anthracycline indicated for second-line treatment of platinum- and paclitaxel-refractory ovarian cancer.	liposomal doxorubicin	33-38	glycosylphosphatidylinositol specific phospholipase D1	Homo sapiens	47-50	
15717739-3	2004	Pegylated liposomal doxorubicin (Doxil/Caelyx [PLD]), is the only liposomal anthracycline indicated for second-line treatment of platinum- and paclitaxel-refractory ovarian cancer.	liposomal doxorubicin	39-45	glycosylphosphatidylinositol specific phospholipase D1	Homo sapiens	47-50	
15717742-4	2004	Direct comparisons to conventional doxorubicin therapy showed comparable efficacy but significantly lower risk of cardiotoxicity with pegylated liposomal doxorubicin (Doxil/Caelyx [PLD]) therapy.	liposomal doxorubicin	173-179	glycosylphosphatidylinositol specific phospholipase D1	Homo sapiens	181-184	
15717744-4	2004	Pharmacoeconomic analyses of data from clinical trials in patients with Kaposi"s sarcoma determined that the overall cost to achieve objective response was substantially lower with pegylated liposomal doxorubicin (Doxil/Caelyx [PLD]) than with liposomal daunorubicin (DaunoXome [DNX]).	liposomal doxorubicin	214-219	glycosylphosphatidylinositol specific phospholipase D1	Homo sapiens	228-231	
15717744-4	2004	Pharmacoeconomic analyses of data from clinical trials in patients with Kaposi"s sarcoma determined that the overall cost to achieve objective response was substantially lower with pegylated liposomal doxorubicin (Doxil/Caelyx [PLD]) than with liposomal daunorubicin (DaunoXome [DNX]).	liposomal doxorubicin	220-226	glycosylphosphatidylinositol specific phospholipase D1	Homo sapiens	228-231	
15717735-7	2004	In pegylated liposomal doxorubicin (Doxil/Caelyx [PLD]), this delivery system encapsulates doxorubicin within polyethylene glycol-coated liposomes, leading to promising new applications for a well-established drug.	liposomal doxorubicin	36-41	glycosylphosphatidylinositol specific phospholipase D1	Homo sapiens	50-53	
15717735-7	2004	In pegylated liposomal doxorubicin (Doxil/Caelyx [PLD]), this delivery system encapsulates doxorubicin within polyethylene glycol-coated liposomes, leading to promising new applications for a well-established drug.	liposomal doxorubicin	42-48	glycosylphosphatidylinositol specific phospholipase D1	Homo sapiens	50-53	
15717736-1	2004	Encapsulation of doxorubicin in polyethylene glycol-coated liposomes (Doxil/Caelyx [PLD]), was developed to enhance the safety and efficacy of conventional doxorubicin.	liposomal doxorubicin	76-82	glycosylphosphatidylinositol specific phospholipase D1	Homo sapiens	84-87	
33500617-1	2021	Background: Doxil  (PEGylated liposomal doxorubicin, PLD) has been widely used in cancer treatment due to its excellent therapeutic efficacy, but it can simultaneously cause severe adverse effects such as hand-foot syndrome (HFS).	liposomal doxorubicin	12-17	glycosylphosphatidylinositol specific phospholipase D1	Homo sapiens	53-56	
33422061-4	2021	This combination achieves the therapeutic function and simultaneously "grabs" Lipo-Dox  (PEGylated liposomal doxorubicin, PLD) to enhance the cellular internalization and anticancer activity of PLD.	liposomal doxorubicin	78-86	glycosylphosphatidylinositol specific phospholipase D1	Homo sapiens	194-197